


INTRODUCTION



- Drugs: chemical compounds
Targets: Amino-acid sequences/proteins
- The interactions of some (a subset) drugs on some (a subset) targets are known through wet-lab experiments
- There is a **need to complement wet lab experiments by computational means** to narrow down the search space for experimental verification.
- Interactions can be predicted from: known drug-target interaction network, similarities over drugs and those over targets (optional)

Proposed Approach

MOTIVATION

- In [1], it was experimentally shown that matrix factorization-based techniques (where data matrix is factorized into 2 matrices) yield by far the best results.
- Deep learning has been successful in solving various Machine learning problems.

OBJECTIVE FUNCTION

$$\min_{U_1, U_2, U_3, V} \frac{1}{2} \|Y - R \cdot (U_1 U_2 U_3 V)\|_F^2 \text{ such that } U_1, U_2, U_3, V \geq 0$$

LAGRANGIAN BASED FORMULATION

$$\min_{U_1, U_2, U_3, V, X} \frac{1}{2} \|Y - R \cdot (U_1 U_2 U_3 V)\|_F^2 + \frac{\lambda}{2} \|U_1 U_2 U_3 V - X\|_F^2 \text{ such that } X \geq 0, U_1 \geq 0, U_2 \geq 0, U_3 \geq 0, V \geq 0$$

Initialize: $X^0, U_1^0, U_2^0, U_3^0, V^0$
 For $k = 1, 2, \dots$
 $X^{k+1} = P_+ (X^k - \gamma (R^T \cdot (R \cdot X^k - Y) + \lambda (X^k - U_1^k U_2^k U_3^k V^k)))$
 $U_1^{k+1} = P_+ (U_1^k - \theta_1 \lambda (U_1^k U_2^k U_3^k V^k - X^{k+1}) (U_2^k U_3^k V^k)^T)$
 $U_2^{k+1} = P_+ (U_2^k - \theta_2 \lambda (U_1^{k+1})^T (U_1^{k+1} U_2^k U_3^k V^k - X^{k+1}) (U_3^k V^k)^T)$
 $U_3^{k+1} = P_+ (U_3^k - \theta_3 \lambda (U_1^{k+1} U_2^{k+1})^T (U_1^{k+1} U_2^{k+1} U_3^k V^k - X^{k+1}) (V^k)^T)$
 $V^{k+1} = \text{prox}_{\text{sg}(X^{k+1}, U_1^{k+1}, U_2^{k+1}, U_3^{k+1}, \cdot)} (V^k)$

$$G(X, U_1, U_2, U_3, V) = \frac{1}{2} \|Y - R \cdot X\|_F^2 + \frac{\lambda}{2} \|U_1 U_2 U_3 V - X\|_F^2$$

$$(\theta_1, \theta_2, \theta_3, \theta) > 0 \text{ and } \gamma \leq (\|R\|_F^2 + \lambda)^{-1}$$

Algorithm

RESULTS

TABLE I: DATASET DESCRIPTION

Datasets	NR	GPCR	IC	E
Drugs	54	223	201	445
Targets	26	95	204	664
Interactions	90	635	1476	2926

TABLE II: LATENT FACTORS – INPUTS TO ALGORITHMS

Layers	E	GPCR	IC	NR
1 Layer / SVT / PMF / BMC	10	80	85	25
2 Layer	185-25	40-10	100-15	20-10
3 Layer	180-85-15	65-15-5	100-50-10	20-10-5

TABLE III: TABLE SHOWING AUPR

Dataset	1 Layer	2 Layer	3 Layer	SVT	BMC	PMF	GRMF
E	.639	.714	.728	.010	.706	.622	.498
GPCR	.599	.615	.616	.036	.604	.556	.442
IC	.792	.828	.828	.056	.803	.760	.381
NR	.097	.121	.125	.092	.107	.091	.097

TABLE IV: TABLE SHOWING AUC

Dataset	1 Layer	2 Layer	3 Layer	SVT	BMC	PMF	GRMF
E	.877	.897	.899	.496	.879	.855	.573
GPCR	.870	.881	.884	.528	.876	.858	.561
IC	.928	.942	.941	.488	.931	.874	.628
NR	.634	.669	.669	.461	.639	.618	.456

- Evaluation metrics: AUC and AUPR
- Train:Test = 70:30% (done 10 times and average reported)
- **On one hand, going deeper improves abstraction of the latent factors but on the other hand, the number of parameters to learn also increases. Owing to the second fact, over-fitting sets in, the algorithm fails to generalize on the unseen data**

CONCLUSIONS

- *This is the first work that shows how the drug target interaction can be decomposed into more than two factors and estimated via the product of individual factors.*
- *When the associated biological metadata of the drugs/targets is not available, our method yields the best possible results.*
- *The algorithm can be extended to other applications (CF, scRNA-seq imputation, etc) and can be modified to incorporate biological metadata associated with the drugs and targets.*

1. Ezzat, Ali, Min Wu, Xiao-Li Li, and Chee-Keong Kwoh. "Computational prediction of drug-target interactions using chemogenomic approaches: an empirical survey." Briefings in bioinformatics (2018).

LITERATURE Reference

CONTACT Information

Angshul Majumdar
 Indraprastha Institute of Information
 Technology, Delhi
 India
 Contact : angshul@iiitd.ac.in

View
 full paper at

<https://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=8683123>